Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0DDOFD
ADC Name
40460724 ADC A9
Synonyms
ADC A9
   Click to Show/Hide
Organization
ShanghaiTech University
Drug Status
Investigative
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Atezolizumab
  Antibody Info 
Antigen Name
Programmed cell death 1 ligand 1 (CD274)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Rebridge conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.28
uM
CVCL_0419
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
0.36
uM
CVCL_0062
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
0.62
uM
CVCL_0186
Pancreatic ductal adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
3.4
uM
CVCL_0152
Pancreatic ductal adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
6.25
uM
CVCL_1119
Cystic fibrosis, Pancreatic ductal adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.28 uM Low HER2 expression (HER2+)
Method Description
The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-468 cell.
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.36 uM Low HER2 expression (HER2+)
Method Description
The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-231 cell.
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.62 uM Moderate HER2 expression (HER2++)
Method Description
The in vitro antitumor efficacy of ADC was assessed using the BxPc-3 cell.
In Vitro Model Pancreatic ductal adenocarcinoma BxPC-3 cells CVCL_0186
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 3.4 uM Low HER2 expression (HER2+)
Method Description
The in vitro antitumor efficacy of ADC was assessed using the AsPc1 cell.
In Vitro Model Pancreatic ductal adenocarcinoma AsPc1 cells CVCL_0152
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 6.25 uM Moderate HER2 expression (HER2++)
Method Description
The in vitro antitumor efficacy of ADC was assessed using the CFPAC cell.
In Vitro Model Cystic fibrosis, Pancreatic ductal adenocarcinoma CFPAC cells CVCL_1119
References
Ref 1 A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers